Advertisement

Topics

Latest Top Pharmaceutical Companies in Japan NewsRSS

17:33 EDT 21st July 2018 | BioPortfolio

#jobs #lifescience Principal Scientist, Drug Discovery Project Leader – Immunology – San Diego, CA

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Principal Scientist, Drug Discovery Project Leader – Immunology – San Diego, CA .CA-San Diego, By clicking the “Apply” button, I understand that my employment application process with Takeda … Continue reading → Cet article #jobs #lifescience Princi...

Generic cancer pain relief launched in Japan

Japan-based Daiichi Sankyo announced on 15 June 2018 that it had launched a generic version of cancer pain relief Fentos Tape (fentanyl citrate tape).

Takeda Pharma: VISIBLE 1 Study Of Vedolizumab Meets Primary Endpoint

Japan's Takeda Pharmaceutical Co. Ltd. (TKPYY.PK) announced Thursday that new phase 3 data show investigational subcutaneous or SC formulation of Vedolizumab meets primary endpoint in achieving clinical remission at week 52 in patients with moderately to severely active ulcerative colitis.

#jobs #lifescience Marketing Operations and Field Services Manager

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Marketing Operations and Field Services Manager .MA-Cambridge, By clicking the “Apply” button, I understand that my employment application process with Takeda will commence and that I agree with … Continue reading → Cet article #jobs #lifescience Marketing Oper...

#jobs #lifescience Sr Scientist Molecular Genomics Early Target Discovery

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sr Scientist Molecular Genomics Early Target Discovery .CA-San Diego, By clicking the “Apply” button, I understand that my employment application process with Takeda will commence and that I … Continue reading → Cet article #jobs #lifescience Sr Scientist Molec...

Takeda Eyes China Drug Market as its Next Big Opportunity Following Shire Deal

The Chinese biopharma market is booming as more and more companies eye breaking into that rich market. Christophe Weber, chief executive officer of pharma giant Takeda, views its China programs as its second-biggest business behind the United States.

20182023 United States BFS BlowFillSeal Products Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the BFS BlowFillSeal Products market size was xx million USD in United States, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In United States market, the top players include Unither Pharmaceuticals Nephron Pharmaceuticals Takeda Pharmaceuticals Recipharm TRC SIFI Catalent Horizon Pharmaceuticals Unicep Packaging Amanta Health...

20182023 United States Nickel Base Alloy Market Report Status and Outlook [Report Updated: 09032018] Prices from USD $3360

In 2017, the Nickel Base Alloy market size was xx million USD in United States, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In United States market, the top players include SMC ThyssenKrupp VDM Carpenter Imphy Alloys Allegheny Hitachi Metals Nippon Yakin Bao Steel Sumitomo Haynes Daido Steel Foroni Sandvik Deutsche Bo...

Poxel Announces Favorable Results for PXL770 Phase 1b Multiple Ascending Dose Trial and Drug-Drug Interaction Study

PXL770 observed to have a favorable safety and pharmacokinetic profile in the complete Phase 1 program PXL770 is advancing into a Phase 2a proof-of-concept program for NASH POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic...

Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with Three New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)

Broad clinical program to include three studies expected to begin in the third quarter of calendar year 2018 in addition to the now fully enrolled Phase 1b/2a trial of adults with DEE

FDA Approves Pfizer And Astellas Pharma's Xtandi

NewsThis approval makes Xtandi the first and only oral medication FDA-approved for both non-metastatic and metastatic castration-resistant prostate cancer (CRPC).

leon-nanodrugs Supports Takeda in a Feasibility Assessment of leon’s Proprietary MicroJet Reactor (MJR®) Nano-Technology

Munich, Germany, July 17, 2018 / B3C newswire / -- leon-nanodrugs GmbH (“leon”) is pleased to announce that its proprietary MicroJet Reactor (MJR®) nano-technology has been selected by Takeda Pharmaceutical Company Ltd. (Takeda) for a feasibility assessment that could potentially lead to the development of an innovative formulation of one of their current pipeline products. leo

Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology

Seattle-based Presage Biosciences made several key moves today that include a $6 million investment from pharma giants Takeda and Celgene and also tapped a new chief executive officer.

20182023 Philippines Cytotoxic Drug Market Report Status and Outlook [Report Updated: 05032018] Prices from USD $3360

In 2017, the Cytotoxic Drug market size was xx million USD in Philippines, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In Philippines market, the top players include Roche Eli Lilly Celgene Sanofi eisai Sumitomo Dainippon Pharma Merck Seattle Genetics Takeda Haosoh Pharma Novartis AstraZeneca Jazz Pharma Spectrum PharmaS...

20182023 India BFS BlowFillSeal Products Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the BFS BlowFillSeal Products market size was xx million USD in India, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In India market, the top players include Unither Pharmaceuticals Nephron Pharmaceuticals Takeda Pharmaceuticals Recipharm TRC SIFI Catalent Horizon Pharmaceuticals Unicep Packaging Amanta Healthcare CR Doubl...

20182023 UK Fiber Optics Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the Fiber Optics market size was xx million USD in UK, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In UK market, the top players include Prysmian HTGD Furukawa Corning YOFC Futong Fujikura Sumitomo Tongding CommScope Sterlite FiberHome Jiangsu Etern ZTT General Cable Belden Fasten Nexans Kaile ...

20182023 Philippines Power Cables Market Report Status and Outlook [Report Updated: 01032018] Prices from USD $3360

In 2017, the Power Cables market size was xx million USD in Philippines, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In Philippines market, the top players include Prysmian Group Nexans Sumitomo Electric Furukawa General Cable Southwire Leoni LS Cable Systems Fujikura Far East Cable Jiangnan Cable Baosheng Group Hitachi ...

Astellas and Pfizer Win New Prostate Cancer Indication From the FDA for Xtandi

Four months after filing a supplemental New Drug Application with the U.S. Food and Drug Administration, Astellas and Pfizer snagged regulatory approval for Xtandi as a treatment for non-metastatic Castration-Resistant Prostate Cancer (CRPC).

20182023 India Power Cables Market Report Status and Outlook [Report Updated: 01032018] Prices from USD $3360

In 2017, the Power Cables market size was xx million USD in India, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In India market, the top players include Prysmian Group Nexans Sumitomo Electric Furukawa General Cable Southwire Leoni LS Cable Systems Fujikura Far East Cable Jiangnan Cable Baosheng Group Hitachi Encore Wire...

20182023 UK Nickel Base Alloy Market Report Status and Outlook [Report Updated: 09032018] Prices from USD $3360

In 2017, the Nickel Base Alloy market size was xx million USD in UK, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In UK market, the top players include SMC ThyssenKrupp VDM Carpenter Imphy Alloys Allegheny Hitachi Metals Nippon Yakin Bao Steel Sumitomo Haynes Daido Steel Foroni Sandvik Deutsche Bohler Edelstahl Mits...

20182023 Malaysia BFS BlowFillSeal Products Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the BFS BlowFillSeal Products market size was xx million USD in Malaysia, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In Malaysia market, the top players include Unither Pharmaceuticals Nephron Pharmaceuticals Takeda Pharmaceuticals Recipharm TRC SIFI Catalent Horizon Pharmaceuticals Unicep Packaging Amanta Healthcare CR...

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide), followi...

20182023 United States Power Cables Market Report Status and Outlook [Report Updated: 01032018] Prices from USD $3360

In 2017, the Power Cables market size was xx million USD in United States, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In United States market, the top players include Prysmian Group Nexans Sumitomo Electric Furukawa General Cable Southwire Leoni LS Cable Systems Fujikura Far East Cable Jiangnan Cable Baosheng Group Hitach...

20182023 UK BFS BlowFillSeal Products Market Report Status and Outlook [Report Updated: 15062018] Prices from USD $3360

In 2017, the BFS BlowFillSeal Products market size was xx million USD in UK, and it will be xx million USD in 2023, with a CAGR of xx% between 2017 and 2023.In UK market, the top players include Unither Pharmaceuticals Nephron Pharmaceuticals Takeda Pharmaceuticals Recipharm TRC SIFI Catalent Horizon Pharmaceuticals Unicep Packaging Amanta Healthcare CR DoubleCrane...

Takeda Multiple Myeloma Post-Transplant Therapy Meets Primary Endpoint

NewsThe Phase 3 trial evaluated the effect of Ninlaro (ixazomib) as a maintenance therapy in adult patients diagnosed with multiple myeloma who responded to high-dose therapy and autologous stem cell transplant.

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Top Pharmaceutical Companies in Japan market research data and corporate reports here